The short version of TB-500 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
=== Modulated drug release and zero-order drug release === Many scientists worked to create oral formulations that could maintain a constant drug level because of the ability of drug release at a zero-order rate blood's concentration. However, a few physiological restrictions made it challenging to create such oral formulations. First, because the lower parts of the intestine have a decreased capacity for absorption, the medication absorption typically declines as an oral formulation moves from the stomach to the intestine. The decreased drug amount released from the formulation over time frequently made this condition worse. Phenylpropanolamine HCl release from was the only instance of sustaining consistent blood concentration for roughly 16 hours.
Klaus Biemann (November 2, 1926 – June 2, 2016) was an Austrian-American professor of chemistry at the Massachusetts Institute of Technology. His work centered on structural analysis in organic and biochemistry. He has been called the "father of organic mass spectrometry" but was particularly noted for his role in advancing protein sequencing with tandem mass spectrometry following pioneering work conducted in this area by Michael Barber.
Flunarizine, sold under the brand name Sibelium among others, is a drug classified as a calcium antagonist which is used for various indications. It is not available by prescription in the United States or Japan. The drug was discovered at Janssen Pharmaceutica (R14950) in 1968.
== Further reading == Agashe, Shruti; Petak, Steven (2018). "Cardiac Autonomic Neuropathy in Diabetes Mellitus". Methodist DeBakey Cardiovascular Journal. 14 (4): 251–256. doi:10.14797/mdcj-14-4-251. PMC 6369622. PMID 30788010. Itch, Hiroshi; Uebori, Seiji; Asai, Mahito; Kashiwaya, Tagui; Atoh, Keita; Making, Isao (2003). "Early Detection of Orthostatic Hypotension by Quantitative Sudomotor Axon Reflex Test (QSART) in Type 2 Diabetic Patients". Internal Medicine. 42 (7): 560–564. doi:10.2169/internalmedicine.42.560. PMID 12879946. Yajnik, C.S.; Kantikar, V.; Pande, A.; Deslypere, J.-P.; Dupin, J.; Calvet, J.-H.; Bauduceau, B. (April 2013). "Screening of cardiovascular autonomic neuropathy in patients with diabetes using non-invasive quick and simple assessment of sudomotor function". Diabetes & Metabolism. 39 (2): 126–131. doi:10.1016/j.diabet.2012.09.004. PMID 23159130. Gerrett, Nicola; Griggs, Katy; Redortier, Bernard; Voelcker, Thomas; Kondo, Narihiko; Havenith, George (1 August 2018). "Sweat from gland to skin surface: production, transport, and skin absorption" (PDF). Journal of Applied Physiology. 125 (2): 459–469. doi:10.1152/japplphysiol.00872.2017. PMID 29745799. S2CID 13675424. Quinton, Paul M. (June 2007). "Cystic Fibrosis: Lessons from the Sweat Gland". Physiology. 22 (3): 212–225. doi:10.1152/physiol.00041.2006. PMID 17557942. Gibbons, Christopher H; Wang, Ningshan; Freeman, Roy (December 2010). "Capsaicin Induces Degeneration of Cutaneous Autonomic Nerve Fibers". Annals of Neurology. 68 (6): 888–898. doi:10.1002/ana.22126. PMC 3057686. PMID 21061393.
Sources: en.wikipedia.org
Glyceroneogenesis is a metabolic pathway which synthesizes glycerol 3-phosphate (used to form triglycerides) from precursors other than glucose. Usually, glycerol 3-phosphate is generated from glucose by glycolysis, in the liquid of the cell's cytoplasm (the cytosol). Glyceroneogenesis is used when the concentrations of glucose in the cytosol are low, and typically uses pyruvate as the precursor, but can also use alanine, glutamine, or any substances from the TCA cycle. The main regulator enzyme for this pathway is an enzyme called phosphoenolpyruvate carboxykinase (PEPC-K), which catalyzes the decarboxylation of oxaloacetate to phosphoenolpyruvate. Glyceroneogenesis is observed mainly in adipose tissue, and in the liver. A significant biochemical pathway regulates cytosolic lipid levels. Intense suppression of glyceroneogenesis may lead to metabolic disorders such as type 2 diabetes.
This act was followed by reorganisational measures approved by the French parliament early in 1957 that ensured a large degree of self-government for individual territories. Upper Volta became an autonomous republic in the French community on 11 December 1958. Upper Volta achieved independence on 5 August 1960. The first president, Maurice Yaméogo, was the leader of the Voltaic Democratic Union (UDV). The 1960 constitution provided for election by universal suffrage of a president and a national assembly for five year terms; however, soon after coming to power, Yaméogo banned all political parties other than the UDV.
== Clinical significance == Selenium is a vital nutrient in animals, including humans. About 25 different selenocysteine-containing selenoproteins have so far been observed in human cells and tissues. Since lack of selenium deprives the cell of its ability to synthesize selenoproteins, many health effects of low selenium intake are believed to be caused by the lack of one or more specific selenoproteins. Three selenoproteins, TXNRD1 (TR1), TXNRD2 (TR3) and glutathione peroxidase 4 (GPX4), have been shown to be essential in mouse knockout experiments. On the other hand, too much dietary selenium causes toxic effects and can lead to selenium poisoning. The threshold between essential and toxic concentrations of this element is rather narrow with a factor in the range of 10-100. Mutations in Selenoprotein N (SELENON, formerly SEPN1) in humans cause a subtype of congenital muscular dystrophy known as SELENON-related myopathy.
Sources: en.wikipedia.org
=== United Kingdom === In 1902, Force wheat flakes became the first ready-to-eat breakfast cereal introduced into the United Kingdom. The cereal, and the Sunny Jim character, achieved wide success in Britain, at its peak in 1930 selling 12.5 million packages in one year.
By 1948, Lilly employees worked in 35 countries, most of them as sales representatives in Latin America, Asia, and Africa. After three generations of Lilly family leadership under company founder, Col. Eli Lilly, his son, Josiah K. Lilly Sr., and two grandsons, Eli Lilly Jr. and Josiah K. Lilly Jr., the company announced a reorganization in 1944 that prepared the way for future expansion and the eventual separation of company management from its ownership. In 1945, Lilly began a major expansion effort that included two manufacturing operations in Indianapolis. The company purchased the massive Curtiss-Wright propeller plant on Kentucky Avenue, west of the company's McCarty Street operation. When renovation was completed in mid-1947, the Kentucky Avenue location manufactured antibiotics and capsules and housed the company's shipping department. By 1948, Lilly employed nearly 7,000 people. After World War II, patents and research records belonging to IG Farben, which included Farbwerke Hoechst, were confiscated by the Allies. The U.S. Department of Commerce made the expropriated patent rights available to American pharmaceutical companies for $1; Lilly acquired the rights to methadone. In 1947, Lilly became the first distributor of methadone in the United States and marketed it under the trade name Dolophine. Methadone is an analgesic that is also widely used in the treatment of opioid use disorder.
Shaanxi Zhongbang Pharma-Tech Co., Ltd.-Supply of Epidermal Growth Factor EGF at the Human Protein Reference Database Archived 2005-05-03 at the Wayback Machine. Epidermal+growth+factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EGF model in BioModels database
The soybean oil emulsion does not harm normal human cells, or the cells of most other higher organisms, with the exceptions of sperm cells and blood cells, which are vulnerable to nanoemulsions due to the peculiarities of their membrane structures. For this reason, these nanoemulsions are not used intravenously (IV). The most effective application of this type of nanoemulsion is for the disinfecting of surfaces. Some types of nanoemulsion have been shown to effectively destroy HIV-1 and tuberculosis pathogens on non-porous surfaces.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.